Novartis data underpin long-term efficacy of Aimovig® where other treatments have failed

NEXT STORY
Novartis data show Aimovig® cuts acute migraine medication days by half in patients who failed prior preventive therapies
PREV STORY
ObsEva appoints industry expert as Chief Medical Officer to further advance its Phase 3 clinical programs
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Life Foundation Offers 2016 Life Grants to Assist Those with Infertility

CHICAGO, April 12, 2016 (GLOBE NEWSWIRE) -- The Kevin J. Lederer Life Foundation, a ...

author_avatar
NASDAQ Market News

High Value Care Key to Value Based Success for Long Term Care: RowdMap, Inc. Speaks at Optimal Aging Conference with AARP, KentuckyOne Health

LOUISVILLE, Ky., June 9, 2016 (GLOBE NEWSWIRE) -- via PRWEB - Kelly Krawiec MEd, ...

author_avatar
NASDAQ Market News

iTeos Announces New Data for its Anti-TIGIT Antibody, EOS-448, at the American Society of Hematology Annual Meeting and TIGIT Therapies Digital Summit 2021

author_avatar
NASDAQ Market News